luspatercept sold brand name reblozyl medication used treatment anemia beta thalassemia myelodysplastic us food drug administration fda considers firstinclass luspatercept indicated treatment adults transfusiondependent anemia due low low intermediaterisk myelodysplastic syndromes mds ring sideroblasts unsatisfactory response ineligible erythropoietinbased luspatercept indicated treatment adults transfusiondependent anaemia associated beta possible adverse effects include temporary bone pain joint pains arthralgias dizziness elevated blood pressure hypertension elevated uric acid levels hyperuricemia also increased risk thrombosis blood clots patients risk factors thrombosis taking luspatercept recombinant fusion protein derived human activin receptor type iib actriib linked protein derived immunoglobulin binds tgf transforming growth factor beta superfamily ligands reduce smad signaling reduction smad signaling leads enhanced erythroid phase iii trials evaluated efficacy luspatercept treatment anemia hematological disorders beta myelodysplastic developed acceleron pharma collaboration us food drug administration fda granted approval november treatment anemia lack red blood cells adult patients beta thalassemia require regular red blood cell rbc luspatercept approved medical use european union june us food drug administration fda awarded orphan drug status fast track designation luspatercept evaluated use adults nontransfusion dependent beta drug article relating blood blood forming organs stub help wikipedia expanding ithttpsenwikipediaorgwikiluspatercept